Investigational drug · Phase 3
AK105
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Hepatocellular Carcinoma (HCC).
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 20, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
37
Any phase or sponsor naming "AK105"
First trial start
2020
Aug 11, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AK105", any sponsor or status.
- Phase 226
Conditions studied
As listed on its trial records.
- Advanced Hepatocellular Carcinoma (HCC)
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AK105" as an intervention, largest first.
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Pivotal-lookingActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04344158 · 648 participants (planned) · Start Aug 11, 2020 · Primary completion Dec 2026
Drug: AK105 Injection; Anlotinib Hydrochloride Capsules and 1 more · For: Advanced Hepatocellular Carcinoma (HCC)
Sites: Bengbu, China; Hefei, China; Beijing, China · 81 sites in all
- A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction AdenocarcinomaPivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04385550 · 528 participants (planned) · Start May 20, 2020 · Primary completion Oct 31, 2023
Drug: Anlotinib hydrochloride capsule; AK105 injection and 2 more · For: Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
Sites: Hefei, China; Beijing, China; Fuzhou, China · 45 sites in all
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung CancerPivotal-lookingCompleted
AkesoIndustry
NCT03866993 · 350 participants · Start Dec 20, 2018 · Primary completion Oct 8, 2020
Drug: AK105; Paclitaxel and 2 more · For: Lung Cancer Non-small Cell Stage IV; Squamous Cell Lung Cancer
Sites: Shanghai, China; Beijing, China
- A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaPivotal-lookingActive, not recruiting
AkesoIndustry
NCT04974398 · 296 participants · Start Aug 16, 2021 · Primary completion Feb 23, 2026
Drug: Penpulimab; placebo · For: Nasopharyngeal Carcinoma
Sites: Duarte, California; Atlanta, Georgia; Ann Arbor, Michigan · 56 sites in all
- Efficacy and Safety of Penpulimab Combined With Anlotinib and ChemotherapyPivotal-lookingRecruiting
Xijing HospitalAcademic, hospital or other
NCT06586242 · 194 participants (planned) · Start Apr 3, 2023 · Primary completion Apr 2025
Drug: Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin · For: Esophageal Cancer
Sites: Xi'an, China
- A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLCPivotal-lookingNot yet recruiting
Yang Fan, MDAcademic, hospital or other
NCT07086326 · 164 participants (planned) · Start Jul 31, 2025 · Primary completion Dec 30, 2026
Drug: Ivonescimab+Chemo; Penpulimab+Chemo · For: NSCLC; Neoadjuvant Therapy; Immunotherapy and 2 more
Sites: Beijing, China; Changsha, China; Shanghai, China · 5 sites in all
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung CancerPivotal-lookingTerminated
AkesoIndustry
NCT03866980 · 164 participants · Start Nov 27, 2018 · Primary completion Jun 30, 2023
Drug: AK105; carboplatin and 3 more · For: Lung Cancer Non-small Cell Stage IV
Sites: Beijing, China; Shanghai, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04207463 · 150 participants (planned) · Start Jun 3, 2020 · Primary completion Dec 31, 2020
Drug: AK105; Anlotinib · For: Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Sites: Beijing, China; Nanjing, China; Harbin, China · 7 sites in all
- A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest CancerStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04203719 · 140 participants (planned) · Start May 9, 2020 · Primary completion Dec 31, 2020
Drug: AK105; Anlotinib · For: Advanced Head, Neck and Chest Cancer
Sites: Beijing, China
- A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid TumorPivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04291248 · 138 participants (planned) · Start Mar 2020 · Primary completion Dec 2022
Drug: AK105; Anlotinib · For: MSI-H or dMMR Advanced Solid Tumors
Sites: Beijing, China; Harbin, China; Nanjing, China · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Penpulimab: A next-generation Fc-engineered PD-1 inhibitor in cancer immunotherapy.
Easmin S, Palai S, Saha S, et al. · Crit Rev Oncol Hematol 2026
- Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma.
Hockett JJ, Keller ME, Reeves DJ · Ann Pharmacother 2026
- Graph convolutional network-derived pathomics and clinical integration for predicting chemoimmunotherapy response in advanced lung squamous cell carcinoma: a multicenter study.
Wang D, Mu S, Zhang M, et al. · J Transl Med 2026
- A pathomics model for predicting response to chemo-immunotherapy in lung squamous cell carcinoma: A multicenter study.
Wang D, Mu S, Zhang M, et al. · Lung Cancer 2026
- Cost-effectiveness analysis of penpulimab plus carboplatin-paclitaxel as first-line treatment for metastatic squamous non-small-cell lung cancer in China.
Wang L, Chen J, Lin L, et al. · Health Econ Rev 2025
Also in development for Advanced Hepatocellular Carcinoma (HCC)
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- B7-H3 CAR-NKEB-G3B7-NK dual-target CAR-NK cells, Dual-target GPC3Phase 22 trials
Beijing Biotech · Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, Relapsed Neuroblastoma
- WGI-0301Phase 22 trials
Zhejiang Haichang Biotech Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC), Hepato Cellular Carcinoma (HCC), Renal Cell Cancer
- HA131Phase 21 trial
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.